- blocking peptide
- coli recombinant
- First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial.
- The New Paradigms in Clinical Research: From Early Access Programs to the Novel Therapeutic Approaches for Unmet Medical Needs.
- What Drives Innovation: The Canadian Touch on Liposomal Therapeutics.
DM us for scientific support 8AM - 1AM UTC Mon - Fri. Serving life science researchers globally to achieve their mission, faster.
It was an honor today to receive 3 #EXA22 awards🥇 🥈 🥉! So great to see teams coming together to create fulfilling work environments and companies raising the standards of #EmployeeExperience #TalentDevelopment #DiversityandInclusion @awardsinter #growingwithabcam #weareabcam3
All #epigenetics aficionados are invited to join us on Monday at our hybrid forum featuring @rcollepardo from @Cambridge_Uni and @MAChristoLab from @BabrahamUK!
Register to join in-person or online.
@EpigeneticsClub @hendersi @RuggGunnLab @rcollepardo
There is still time to register! Join us on May 23 at @TheCrick in London (or online) to hear @dynamicMT from @WTcell presenting her work on dynamic remodeling of the microtubule cytoskeleton throughout #mitosis.
@DeRobertus @Thorpelab #cellcycle
#ICYMI: Our very own Jayne Hammersley spoke with @EmmaEasthope about why the research community is opting more and more for recombinant antibodies. Read the article here:
When you partner with us, our dedicated team of scientific experts will help you overcome unexpected obstacles. Watch our webinar to see how we worked with Tiaki Therapeutics to support its translational biomarker program.